| Renal Cell Carcinoma
Welireg vs Cabometyx
Side-by-side clinical, coverage, and cost comparison for renal cell carcinoma.Deep comparison between: Welireg vs Cabometyx with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCabometyx has a higher rate of injection site reactions vs Welireg based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cabometyx but not Welireg, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Welireg
Cabometyx
At A Glance
Oral
Once daily
HIF-2α inhibitor
Oral
Once daily
Tyrosine kinase inhibitor
Indications
- Von Hippel-Lindau Syndrome
- Renal Cell Carcinoma
- Pheochromocytoma
- Paraganglioma
- Renal Cell Carcinoma
- Liver carcinoma
- Well Differentiated Pancreatic Endocrine Neoplasm
- Neuroendocrine Tumors
Dosing
Von Hippel-Lindau Syndrome Adults: 120 mg orally once daily. Pediatric patients >=12 years: 120 mg orally once daily if >=40 kg or 80 mg orally once daily if <40 kg.
Renal Cell Carcinoma Adults: 120 mg orally once daily.
Pheochromocytoma Adults: 120 mg orally once daily. Pediatric patients >=12 years: 120 mg orally once daily if >=40 kg or 80 mg orally once daily if <40 kg.
Paraganglioma Adults: 120 mg orally once daily. Pediatric patients >=12 years: 120 mg orally once daily if >=40 kg or 80 mg orally once daily if <40 kg.
Renal Cell Carcinoma (single agent) 60 mg orally once daily until disease progression or unacceptable toxicity.
Renal Cell Carcinoma (+ nivolumab) 40 mg orally once daily in combination with nivolumab (240 mg every 2 weeks or 480 mg every 4 weeks, or subcutaneous formulations) until disease progression or unacceptable toxicity.
Liver carcinoma 60 mg orally once daily until disease progression or unacceptable toxicity.
Differentiated Thyroid Cancer, Well Differentiated Pancreatic Endocrine Neoplasm, Neuroendocrine Tumors 60 mg orally once daily for adults and pediatric patients >=40 kg; 40 mg orally once daily for pediatric patients 12 years and older with bodyweight <40 kg, until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) Decreased hemoglobin, fatigue, increased creatinine, headache, dizziness, increased glucose, nausea, musculoskeletal pain, decreased lymphocytes, increased alanine aminotransferase, decreased sodium, increased potassium, increased aspartate aminotransferase, anemia, dyspnea, increased calcium, decreased leukocytes, increased alkaline phosphatase.
Serious Anemia, hypoxia, hemorrhage, pneumonia, pleural effusion, pyelonephritis, hypertension, retinal detachment, central retinal vein occlusion, anaphylaxis reaction.
Postmarketing Not reported in label.
Most common (>=25%) Diarrhea, fatigue, palmar-plantar erythrodysesthesia, hypertension, decreased appetite, nausea, vomiting, weight decreased, constipation, stomatitis, rash, hypothyroidism, musculoskeletal pain.
Serious Hemorrhage, perforations and fistulas, thromboembolic events, hypertensive crisis, cardiac failure, hepatotoxicity, adrenal insufficiency, proteinuria, osteonecrosis of the jaw, reversible posterior leukoencephalopathy syndrome, thyroid dysfunction, hypocalcemia.
Postmarketing Arterial (including aortic) aneurysms, dissections, and rupture.
Pharmacology
Belzutifan is a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor that binds to HIF-2α and blocks its interaction with HIF-1β, leading to reduced transcription of HIF-2α target genes associated with cellular proliferation, angiogenesis, and tumor growth.
Cabozantinib is a tyrosine kinase inhibitor that inhibits MET, VEGFR-1/-2/-3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT-3, and TIE-2 - receptor tyrosine kinases involved in oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Welireg
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Cabometyx
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Welireg
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Cabometyx
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Welireg
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Cabometyx
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/fillfill
Welireg Co-Pay Coupon Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Cabometyx.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
WeliregView full Welireg profile
CabometyxView full Cabometyx profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.